Lineage Cell Therapeutics, Inc.LCTXEarnings & Financial Report
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to eithe...
LCTX Q4 FY2025 Key Financial Metrics
Revenue
$6.6M
Gross Profit
N/A
Operating Profit
$-6.5M
Net Profit
$851.0K
Gross Margin
N/A
Operating Margin
-99.1%
Net Margin
12.9%
YoY Growth
130.4%
EPS
$0.00
Lineage Cell Therapeutics, Inc. Q4 FY2025 Financial Summary
Lineage Cell Therapeutics, Inc. reported revenue of $6.6M (up 130.4% YoY) for Q4 FY2025, with a net profit of $851.0K (up 126.0% YoY) (12.9% margin).
Key Financial Metrics
| Total Revenue | $6.6M |
|---|---|
| Net Profit | $851.0K |
| Gross Margin | N/A |
| Operating Margin | -99.1% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Lineage Cell Therapeutics, Inc. Q4 FY2025 revenue of $6.6M breaks down across 2 segments, led by Collaboration Revenues at $6.3M (94.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Collaboration Revenues | $6.3M | 94.8% |
| Other | $345.0K | 5.2% |
Lineage Cell Therapeutics, Inc. Revenue by Segment — Quarterly Trend
Lineage Cell Therapeutics, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Collaboration Revenues and Other) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Collaboration Revenues | $6.3M | $3.5M | $2.5M | $1.3M |
| Other | $345.0K | $137.0K | $233.0K | $232.0K |
Lineage Cell Therapeutics, Inc. Annual Revenue by Year
Lineage Cell Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $14.6M).
Lineage Cell Therapeutics, Inc. Quarterly Revenue & Net Profit History
Lineage Cell Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $6.6M | +130.4% | $851.0K | 12.9% |
| Q3 FY2025 | $3.7M | -2.6% | $-29.8M | -809.0% |
| Q2 FY2025 | $2.8M | +96.4% | $-30.5M | -1101.8% |
| Q1 FY2025 | $1.5M | +4.0% | $-4.1M | -275.6% |
| Q4 FY2024 | $2.9M | +37.4% | $-3.3M | -114.1% |
| Q3 FY2024 | $3.8M | +203.3% | $-3.0M | -80.3% |
| Q2 FY2024 | $1.4M | -56.3% | $-5.8M | -409.1% |
| Q1 FY2024 | $1.4M | -39.5% | $-6.5M | -453.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $1.4M | $3.8M | $2.9M | $1.5M | $2.8M | $3.7M | $6.6M |
| YoY Growth | -39.5% | -56.3% | 203.3% | 37.4% | 4.0% | 96.4% | -2.6% | 130.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $108.5M | $102.8M | $96.6M | $113.2M | $111.8M | $90.8M | $89.6M | $112.6M |
| Liabilities | $37.5M | $35.9M | $31.8M | $36.2M | $34.1M | $43.7M | $68.8M | $69.2M |
| Equity | $72.4M | $68.3M | $66.2M | $78.4M | $79.0M | $48.4M | $22.0M | $44.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.8M | $-5.2M | $-5.8M | $-6.3M | $-4.9M | $-5.5M | $-3.6M | $-4.9M |